Scholars@Duke
Rami Nayef Al-Rohil

Rami Nayef Al-Rohil

Adjunct Associate Professor in the Department of Pathology
Pathology
rami.alrohil@duke.edu
Duke Box 3712, Yellow Zone Room 3108, Durham, NC 27710
Duke Box 3712, 3108 Yellow Zone, Duke South, Durham, NC 27710

Scholarly Works - Other

Supplementary Figure S4 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <p>Supplementary Figure S4: Protein Expression Patterns Did Not Predict KRT-232 Responsiveness in Group III PDX lines Compared to Group II PDX Lines</p> ... Full text Cite

Data from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <div>AbstractPurpose:<p>Over 60% of patients with melanoma respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on <i>BRAF</i> mutatio ... Full text Cite

Supplementary Figure S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <p>Supplementary Figure S1A: Validation of PDX tumors: Short Tandem Repeat (STR) Analysis</p> ... Full text Cite

Supplementary Figure S3 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <p>Supplementary Figure S3: Alterations in Protein Expression Associated with D+T Response in Group I PDX lines.</p> ... Full text Cite

Supplementary Figure S3 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <p>Supplementary Figure S3: Alterations in Protein Expression Associated with D+T Response in Group I PDX lines.</p> ... Full text Cite

Data from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <div>AbstractPurpose:<p>Over 60% of patients with melanoma respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on <i>BRAF</i> mutatio ... Full text Cite

Supplementary Figure S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <p>Supplementary Figure S1A: Validation of PDX tumors: Short Tandem Repeat (STR) Analysis</p> ... Full text Cite

Supplementary Figure S4 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Other · March 31, 2023 <p>Supplementary Figure S4: Protein Expression Patterns Did Not Predict KRT-232 Responsiveness in Group III PDX lines Compared to Group II PDX Lines</p> ... Full text Cite